Collegium Pharmaceutical
COLL
117 hedge funds and large institutions have $345M invested in Collegium Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 26 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.64% less ownership
Funds ownership: 92.37% → 89.72% (-2.6%)
9% less funds holding
Funds holding: 128 → 117 (-11)
15% less capital invested
Capital invested by funds: $406M → $345M (-$60.8M)
23% less call options, than puts
Call options by funds: $191K | Put options by funds: $248K
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$5.74M |
| 2 |
SAM
Silvercrest Asset Management
New York
|
+$5.11M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.14M |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$1.1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6.54M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.08M |
| 3 |
MSL
Mackay Shields LLC
New York
|
-$2.57M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$2.56M |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$2.24M |
COLL Hedge Fund Activity: Q3 2019 in Review
117 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2019, worth a combined $345M — down 15% from $406M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of COLL and 17 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was Renaissance Technologies, adding an estimated $5.74M. The largest seller was Macquarie Group, exiting entirely with an estimated $6.54M sold.
- 117 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2019, down from 128 in Q2 2019.
- Funds reported $345M of Collegium Pharmaceutical stock for Q3 2019, down 15% quarter-over-quarter.
- 17 funds opened new Collegium Pharmaceutical positions in Q3 2019 and 26 closed out, a net change of -9 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2019 was Renaissance Technologies, an estimated $5.74M added.
- The largest Collegium Pharmaceutical seller in Q3 2019 was Macquarie Group, an estimated $6.54M sold.
Based on aggregated 13F filings for Q3 2019.